151 related articles for article (PubMed ID: 14615384)
1. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.
Barata JT; Boussiotis VA; Yunes JA; Ferrando AA; Moreau LA; Veiga JP; Sallan SE; Look AT; Nadler LM; Cardoso AA
Blood; 2004 Mar; 103(5):1891-900. PubMed ID: 14615384
[TBL] [Abstract][Full Text] [Related]
2. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA
J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558
[TBL] [Abstract][Full Text] [Related]
3. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Barata JT; Cardoso AA; Nadler LM; Boussiotis VA
Blood; 2001 Sep; 98(5):1524-31. PubMed ID: 11520803
[TBL] [Abstract][Full Text] [Related]
5. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA
J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439
[TBL] [Abstract][Full Text] [Related]
6. Effects of thrombopoietin, interleukin-3 and the kinase inhibitor K-252a on growth and polyploidization of the megakaryocytic cell line M-07e.
Quentmeier H; Zaborski M; Drexler HG
Leukemia; 1998 Oct; 12(10):1603-11. PubMed ID: 9766506
[TBL] [Abstract][Full Text] [Related]
7. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].
Abroun S; Ishikawa H; Tsuyama N; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Kawano MM
Blood; 2004 Mar; 103(6):2291-8. PubMed ID: 14592826
[TBL] [Abstract][Full Text] [Related]
8. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
9. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
Ju W; Zhang M; Jiang JK; Thomas CJ; Oh U; Bryant BR; Chen J; Sato N; Tagaya Y; Morris JC; Janik JE; Jacobson S; Waldmann TA
Blood; 2011 Feb; 117(6):1938-46. PubMed ID: 21106989
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F.
Brennan P; Babbage JW; Burgering BM; Groner B; Reif K; Cantrell DA
Immunity; 1997 Nov; 7(5):679-89. PubMed ID: 9390691
[TBL] [Abstract][Full Text] [Related]
11. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
12. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice.
Han HS; Jun HS; Utsugi T; Yoon JW
J Autoimmun; 1997 Jun; 10(3):299-307. PubMed ID: 9218758
[TBL] [Abstract][Full Text] [Related]
13. Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes.
Shatrova AN; Mityushova EV; Vassilieva IO; Aksenov ND; Zenin VV; Nikolsky NN; Marakhova II
PLoS One; 2016; 11(12):e0167215. PubMed ID: 27936140
[TBL] [Abstract][Full Text] [Related]
14. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
Behbod F; Erwin-Cohen RA; Wang ME; Trawick BW; Qu X; Verani R; Kahan BD; Stepkowski SM; Kirken RA
J Immunol; 2001 Mar; 166(6):3724-32. PubMed ID: 11238613
[TBL] [Abstract][Full Text] [Related]
15. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
16. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
17. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).
Cheng M; Sexl V; Sherr CJ; Roussel MF
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1091-6. PubMed ID: 9448290
[TBL] [Abstract][Full Text] [Related]
18. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
[TBL] [Abstract][Full Text] [Related]
19. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
20. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
